Clinical indications, safety, and effectiveness of percutaneous image-guided adrenal mass biopsy: an 8-year retrospective analysis in 160 patients
- 2 March 2024
- journal article
- research article
- Published by Springer Nature in Abdominal Radiology
- Vol. 49 (4) , 1231-1240
Abstract
Purpose To assess indications, safety, and effectiveness of percutaneous adrenal mass biopsy in contemporary practice. Methods This institutional review board-approved, retrospective study included all patients undergoing percutaneous image-guided adrenal mass biopsies at an academic health system from January 6, 2015, to January 6, 2023. Patient demographics, biopsy indications, mass size, laboratory data, pathology results, and complications were recorded. Final diagnoses were based on pathology or ≥ 1 year of imaging follow-up when biopsy specimens did not yield malignant tissue. Test performance calculations excluded repeat biopsies. Continuous variables were compared with Student’s t test, dichotomous variables with chi-squared test. Results A total of 160 patients underwent 186 biopsies. Biopsies were indicated to diagnose metastatic disease (139/186; 74.7%), for oncologic research only (27/186; 14.5%), diagnose metastatic disease and oncologic research (15/186; 8%), and diagnose an incidental adrenal mass (5/186; 2.7%). Biopsy specimens were diagnostic in 154 patients (96.3%) and non-diagnostic in 6 (3.8%). Diagnostic biopsies yielded malignant tissue (n = 136), benign adrenal tissue (n = 12), and benign adrenal neoplasms (n = 6) with sensitivity = 98.6% (136/138), specificity = 100% (16/16), positive predictive value = 100% (136/136), and negative predictive value = 88.9% (16/18). Adverse events followed 11/186 procedures (5.9%) and most minor (7/11, 63.6%). The adverse event rate was similar whether tissue was obtained for clinical or research purposes (10/144; 6.9% vs. 1/42; 2.4%, p = 0.27), despite more specimens obtained for research (5.8 vs. 3.7, p < 0.001). Conclusion Percutaneous adrenal mass biopsy is safe, accurate, and utilized almost exclusively to diagnose metastatic disease or for oncologic research. The negative predictive value is high when diagnostic tissue samples are obtained. Obtaining specimens for research does not increase adverse event risk. Graphical AbstractKeywords
This publication has 30 references indexed in Scilit:
- Image-Guided Adrenal and Renal BiopsyTechniques in Vascular and Interventional Radiology, 2010
- Biopsy of pheochromocytomas and paragangliomas: Potential for disasterSurgery, 2009
- American Association Of Clinical Endocrinologists And American Association Of Endocrine Surgeons Medical Guidelines For The Management Of Adrenal IncidentalomasEndocrine Practice, 2009
- Limited Value of Adrenal Biopsy in the Evaluation of Adrenal NeoplasmArchives of Surgery, 2009
- The Incidental Adrenal Mass on CT: Prevalence of Adrenal Disease in 1,049 Consecutive Adrenal Masses in Patients with No Known MalignancyAmerican Journal of Roentgenology, 2008
- Changing Role of Imaging-Guided Percutaneous Biopsy of Adrenal Masses:Evaluation of 50 Adrenal BiopsiesAmerican Journal of Roentgenology, 2004
- Predictive Value of Benign Percutaneous Adrenal Biopsies in Oncology PatientsClinical Radiology, 2002
- Characterization of adrenal masses using unenhanced CT: an analysis of the CT literature.American Journal of Roentgenology, 1998
- Percutaneous CT-Guided Biopsy of Adrenal MassesJournal of Computer Assisted Tomography, 1995
- CT-guided adrenal biopsy: accuracy, safety, and indicationsAmerican Journal of Roentgenology, 1985